Empowered Funds LLC Buys 54,891 Shares of DaVita Inc. $DVA

Empowered Funds LLC increased its stake in shares of DaVita Inc. (NYSE:DVA) by 805.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 61,703 shares of the company’s stock after acquiring an additional 54,891 shares during the quarter. Empowered Funds LLC’s holdings in DaVita were worth $8,790,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. National Pension Service raised its holdings in DaVita by 74.3% in the 1st quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after acquiring an additional 84 shares during the period. Hantz Financial Services Inc. increased its stake in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the period. Y.D. More Investments Ltd bought a new position in shares of DaVita during the first quarter worth approximately $35,000. Mid American Wealth Advisory Group Inc. acquired a new stake in DaVita during the 2nd quarter worth approximately $36,000. Finally, Ameritas Advisory Services LLC bought a new stake in DaVita in the 2nd quarter valued at $47,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on DVA shares. Truist Financial set a $140.00 target price on DaVita in a report on Tuesday, October 14th. Wall Street Zen lowered shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research note on Thursday, November 13th. Bank of America decreased their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a research report on Wednesday, September 10th. Finally, Barclays lowered their target price on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a report on Thursday, October 30th. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $148.00.

DaVita Stock Down 1.0%

DVA opened at $115.40 on Thursday. The stock has a market capitalization of $8.15 billion, a price-to-earnings ratio of 11.88, a P/E/G ratio of 0.91 and a beta of 1.13. DaVita Inc. has a twelve month low of $113.97 and a twelve month high of $179.60. The company has a 50-day simple moving average of $126.60 and a 200 day simple moving average of $134.86.

DaVita (NYSE:DVA) last issued its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a return on equity of 815.62%. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.43 billion. During the same quarter in the previous year, the firm posted $2.59 earnings per share. DaVita’s quarterly revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.